Development of a comprehensive microbial immunotherapy platform with immuno-transcriptomic monitoring for treatment of bladder cancer (DOCMI-BC)

开发用于治疗膀胱癌的具有免疫转录组监测的综合微生物免疫治疗平台（DOCMI-BC）

• 批准号: 10087336
• 金额: $ 25.55万
• 依托单位: PROKARIUM LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10087336
• 关键词: Development; comprehensive; microbial; immunotherapy; platform

Bladder Cancer (BC) affects more than 550,000 people globally every year. With the highest recurrence rate of any known cancer (80%), it is one of the most expensive for the NHS to treat, costing £65M pa (CRUK). Current immunotherapy treatments based on the weakened strain of _Mycobacterium bovis_ (BCG) present a significant challenge, with substantial impact on patient quality of life and high rates of cancer recurrence. Moreover, chemotherapy and other existing immunotherapies have significant side effects and generally poor response rates.Prokarium's therapeutics are positioned to overcome such limitations by leveraging the natural tumor-suppressive properties of proprietary _Salmonella_ bacteria strain ZH9\.Prokarium have previously shown that ZH9 has superior effectiveness compared to the current standard-of-care BCG in early-stage BC. This has enabled an upcoming first clinical trial and, in collaboration with Switzerland based University of Lausanne and Novigenix, Prokarium aims to expand upon this work to support the further development of ZH9 for BC by exploring the efficacy and mechanism of action of ZH9 in more advanced muscle invasive BC (MIBC), both as a standalone treatment and when administered in combination with other therapies, either already licensed or in development for BC.The incorporation of Novigenix technology will allow understanding of the mechanism of action of the therapy and identification of biomarkers of response that can be used to improve future clinical trials and ultimately provide better treatments to BC patients.

膀胱癌（BC）每年影响全球55万多人。由于任何已知癌症的复发率最高（80％），它是NHS治疗最昂贵的癌症之一，耗资6500万英镑PA（CRUK）。目前的免疫疗法基于_mycobacterium bovis_（BCG）疲软的菌株提出了重大挑战，对患者的生活质量和高癌症复发率产生了重大影响。此外，化学疗法和其他现有的免疫疗法具有显着的副作用，总体上反应率较差。原始的治疗方法可以通过利用专有_salmonella_细菌菌株ZH9 \ .prokarium的自然肿瘤抑制特性来克服这种局限性。这已经使即将到来的首次临床试验，并与位于瑞士的洛桑大学和诺维尼克斯合作，培养基旨在扩大这项工作，以支持ZH9的进一步发展，通过探索更先进的Muscle BC（MIBC（MIBC）），以探索ZH9的有效性和作用机制，并在其他方面进行了治疗，或者在其他方面进行了处理，或者是在其他方面进行的，或者是在其他方面进行的，或者在其他方面进行了处理，或者在其他方面进行了处理，或者在其他方面进行了处理，或者在其他方面进行了处理，或者在其他方面进行了处理，或者在其他方面进行了处理，或者在其他方面进行了处理。对于卑诗省。Novigenix技术的保险将允许了解治疗的作用机理和鉴定反应的生物标志物，可用于改善未来的临床试验，并最终为卑诗省患者提供更好的治疗方法。